Mednax Inc (MD)
Solvency ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.00 | 0.05 | 0.06 | 0.07 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | 0.00 | 0.12 | 0.11 | 0.12 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.25 | 0.00 | 0.14 | 0.13 | 0.14 |
| Financial leverage ratio | 2.61 | 2.40 | 2.45 | 2.55 | 2.63 | 2.72 | 2.80 | 2.67 | 3.04 | 3.13 | 3.16 | 3.24 | 4.48 | 4.26 | 4.10 | 2.90 | 2.77 | 2.90 | 2.07 | 2.05 |
The solvency ratios of Pediatrix Medical Group Inc indicate the company's ability to meet its financial obligations in the long term.
The Debt-to-assets ratio has ranged from 0.27 to 0.33 over the past eight quarters, with a current value of 0.29 for Q4 2023. This ratio suggests that around 29% of the company's total assets are financed by debt, indicating a relatively stable and healthy position.
The Debt-to-capital ratio has fluctuated between 0.40 and 0.45 during the same period, standing at 0.43 in Q4 2023. This ratio implies that approximately 43% of the company's capital structure is funded by debt, which is within reasonable limits but should be monitored for any significant increases.
The Debt-to-equity ratio has shown a wider range of variation, from 0.66 to 0.96, with a current value of 0.75 in Q4 2023. This ratio indicates that 75% of the company's equity is financed by debt, suggesting a higher level of leverage compared to the other solvency ratios.
The Financial leverage ratio has exhibited a similar trend to the Debt-to-assets ratio, varying between 2.40 and 2.80 over the past two years, with a ratio of 2.61 in Q4 2023. This ratio reflects the company's level of financial risk and indicates how much the company's assets are financed by debt.
Overall, Pediatrix Medical Group Inc appears to have maintained a relatively stable solvency position over the analyzed period, with moderate levels of debt relative to its assets, capital, and equity. However, the company should continue to monitor these ratios to ensure they remain at healthy levels and do not indicate increasing financial risk.
Coverage ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | -0.15 | 3.96 | 4.26 | 4.51 | 3.14 | 3.43 | 3.10 | 2.86 | 3.30 | 1.49 | 0.58 | -6.46 | -6.06 | -5.39 | -15.94 | -9.79 | -11.45 | -11.10 | 0.31 | 1.35 |
Pediatrix Medical Group Inc's interest coverage has exhibited fluctuation over the past eight quarters, ranging from a low of 3.64 in Q1 2022 to a high of 5.08 in Q4 2022. The interest coverage ratio measures the company's ability to meet its interest obligations from its operating income, with higher values indicating a stronger ability to cover interest expenses.
Overall, Pediatrix Medical Group Inc has maintained a relatively healthy interest coverage ratio throughout the period, with an average ratio of approximately 4.41. The trend indicates that the company has generally been able to comfortably cover its interest expenses with its operating income. However, the slight fluctuations in the ratio suggest some variability in the company's ability to cover its interest payments, which may warrant further investigation into the company's financial stability and performance.